Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II brigatinib monotherapy in children and young adults with ALK-positive ALCL, IMT, or other solid tumors
MOH_2023-03-20_012445Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brigatinib in anaplastic large cell lymphoma (ALCL), inflammatory pseudotumor (IPT) and Nonhematologic neoplasms, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose, Pharmacokinetics of brigatinib and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
brigatinib
03
Conditions
anaplastic large cell lymphoma (ALCL)inflammatory pseudotumor (IPT)Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2023-03-20_012445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-20_012445.